Ourania Tatsis Vertex Pharmaceuticals Inc (VRTX) insider trading activity

Ourania Tatsis is EVP, Chief Reg. & Quality Off. of VERTEX PHARMACEUTICALS INC . Currently has a direct ownership of 49,098 shares of VRTX, which is worth approximately $23 Million. The most recent transaction as insider was on Jun 03, 2024, when has been sold 2,175 shares (Common Stock) at a price of $460.0 per share, resulting in proceeds of $1,000,500. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 49.1K

0% 3M change

0.95% 12M change

Total Value Held $23 Million

Ourania Tatsis Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jun 03 2024	SELL Open market or private sale	$1,000,500 $460.0 p/Share	2,175 Reduced 4.24%	49,098 Common Stock
May 31 2024	SELL Open market or private sale	$1,001,250 $445.0 p/Share	2,250 Reduced 4.2%	51,273 Common Stock
May 30 2024	SELL Open market or private sale	$1,031,908 $439.11 p/Share	2,350 Reduced 4.21%	53,523 Common Stock
Feb 26 2024	SELL Open market or private sale	$150,697 $425.7 p/Share	354 Reduced 0.63%	55,804 Common Stock
Feb 23 2024	SELL Payment of exercise price or tax liability	$1,428,793 $431.79 p/Share	3,309 Reduced 5.56%	56,158 Common Stock
Feb 21 2024	SELL Open market or private sale	$151,837 $421.77 p/Share	360 Reduced 0.6%	59,467 Common Stock
Feb 20 2024	SELL Open market or private sale	$201,979 $420.79 p/Share	480 Reduced 0.8%	59,827 Common Stock
Feb 20 2024	SELL Payment of exercise price or tax liability	$1,418,616 $420.58 p/Share	3,373 Reduced 5.3%	60,307 Common Stock
Feb 16 2024	SELL Payment of exercise price or tax liability	$1,907,620 $424.01 p/Share	4,499 Reduced 6.6%	63,680 Common Stock
Feb 12 2024	SELL Open market or private sale	$131,955 $420.24 p/Share	314 Reduced 0.46%	68,179 Common Stock
Feb 09 2024	SELL Payment of exercise price or tax liability	$887,754 $422.74 p/Share	2,100 Reduced 2.97%	68,493 Common Stock
Feb 07 2024	BUY Grant, award, or other acquisition	-	7,114 Added 9.15%	70,593 Common Stock
Feb 06 2024	BUY Grant, award, or other acquisition	-	14,842 Added 18.95%	63,479 Common Stock
Aug 23 2023	SELL Open market or private sale	$887,500 $355.0 p/Share	2,500 Reduced 4.89%	48,637 Common Stock
Aug 10 2023	SELL Open market or private sale	$1,988,292 $345.79 p/Share	5,750 Reduced 10.11%	51,137 Common Stock
Feb 27 2023	SELL Open market or private sale	$102,047 $288.27 p/Share	354 Reduced 0.62%	56,805 Common Stock
Feb 24 2023	SELL Payment of exercise price or tax liability	$956,408 $289.12 p/Share	3,308 Reduced 5.47%	57,159 Common Stock
Feb 21 2023	SELL Open market or private sale	$140,692 $293.11 p/Share	480 Reduced 0.79%	60,467 Common Stock
Feb 17 2023	SELL Payment of exercise price or tax liability	$1,317,239 $292.85 p/Share	4,498 Reduced 6.87%	60,947 Common Stock
Feb 14 2023	SELL Open market or private sale	$95,395 $298.11 p/Share	320 Reduced 0.49%	65,445 Common Stock
Feb 13 2023	SELL Open market or private sale	$82,148 $298.72 p/Share	275 Reduced 0.42%	65,765 Common Stock
Feb 13 2023	SELL Payment of exercise price or tax liability	$893,288 $298.26 p/Share	2,995 Reduced 4.34%	66,040 Common Stock
Feb 10 2023	SELL Payment of exercise price or tax liability	$405,292 $294.33 p/Share	1,377 Reduced 1.96%	69,035 Common Stock
Feb 01 2023	BUY Grant, award, or other acquisition	-	24,322 Added 25.67%	70,412 Common Stock
Aug 09 2022	SELL Open market or private sale	$419,552 $299.68 p/Share	1,400 Reduced 2.95%	46,090 Common Stock

Also insider at

VERV

Verve Therapeutics, Inc. Healthcare

Ourania Tatsis

EVP, Chief Reg. & Quality Off.

Boston, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells VRTX shares.

Notify only if

Value

Insider Trading

Get notified when an Vertex Pharmaceuticals Inc insider buys or sells VRTX shares.

Notify only if

Operation

Value

Type

News

Receive news related to VERTEX PHARMACEUTICALS INC

Track Activities on VRTX

Account